Agnes Mattsson | Karolinska Institutet

Publications
Public outreach and news

Articles

Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2023;111(5):715-721
Idelalisib (PI3Kδ inhibitor) therapy for patients with relapsed/refractory chronic lymphocytic leukemia: A Swedish nation-wide real-world report on consecutively identified patients
Mattsson A; Sylvan SE; Axelsson P; Ellin F; Kjellander C; Larsson K; Lauri B; Lewerin C; Scharenberg C; Tatting L; Johansson H; Osterborg A; Hansson L
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2020;191(3):426-432
Risk-adapted bendamustine plus rituximab is a tolerable treatment alternative for elderly patients with chronic lymphocytic leukaemia: a regional real-world report on 141 consecutive Swedish patients
Mattsson A; Sylvan SE; Asklid A; Wiggh J; Winqvist M; Lundin J; Mansouri L; Rosenquist R; Johansson H; Osterborg A; Hansson L
Article: LEUKEMIA & LYMPHOMA. 2020;61(9):2136-2144
A real-world study of first-line therapy in 280 consecutive Swedish patients ≥80 years with newly diagnosed diffuse large B-cell lymphoma: very elderly (≥85 years) do well on curative intended therapy
Asklid A; Sylvan SE; Mattsson A; Winqvist M; Johansson H; Osterborg A; Hansson L
Journal article: LEUKEMIA & LYMPHOMA. 2017;58(5):1219-1223
Outcomes of second-line treatment in chronic lymphocytic leukemia - a population-based study from a well defined geographical region between 2003 and 2013
Asklid A; Winqvist M; Sylvan SE; Mattsson A; Bjorgvinsson E; Soltoft F; Repits J; Diels J; Osterborg A; Hansson L

News from KI

Events from KI